C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

Randall J. Olsen, William M. Lydiatt, Scott A Koepsell, Daniel Lydiatt, Sonny L. Johansson, Sabine Naumann, Julia A. Bridge, James R. Neff, Steven Heye Hinrichs, Stefano R. Tarantolo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor. Methods. Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C-erb-B2 (HER2/ neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH). Results. The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen-targeted antibody therapy (trastuzumab) was initiated in two patients. Conclusions. These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities.

Original languageEnglish (US)
Pages (from-to)883-892
Number of pages10
JournalHead and Neck
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2005

Fingerprint

Synovial Sarcoma
Neck
Head
Neoplasms
Extremities
Staining and Labeling
Growth Factor Receptors
Thoracic Wall
Cellular Structures
Fluorescence In Situ Hybridization
Carcinogenesis
Therapeutics
Western Blotting
Epithelial Cells
Immunohistochemistry
Carcinoma
Phenotype
Antigens
Antibodies
Pharmaceutical Preparations

Keywords

  • C-erb-B2
  • HER2/neu
  • Synovial sarcoma
  • Trastuzumab

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Olsen, R. J., Lydiatt, W. M., Koepsell, S. A., Lydiatt, D., Johansson, S. L., Naumann, S., ... Tarantolo, S. R. (2005). C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head and Neck, 27(10), 883-892. https://doi.org/10.1002/hed.20267

C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. / Olsen, Randall J.; Lydiatt, William M.; Koepsell, Scott A; Lydiatt, Daniel; Johansson, Sonny L.; Naumann, Sabine; Bridge, Julia A.; Neff, James R.; Hinrichs, Steven Heye; Tarantolo, Stefano R.

In: Head and Neck, Vol. 27, No. 10, 01.10.2005, p. 883-892.

Research output: Contribution to journalArticle

Olsen, RJ, Lydiatt, WM, Koepsell, SA, Lydiatt, D, Johansson, SL, Naumann, S, Bridge, JA, Neff, JR, Hinrichs, SH & Tarantolo, SR 2005, 'C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck', Head and Neck, vol. 27, no. 10, pp. 883-892. https://doi.org/10.1002/hed.20267
Olsen RJ, Lydiatt WM, Koepsell SA, Lydiatt D, Johansson SL, Naumann S et al. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head and Neck. 2005 Oct 1;27(10):883-892. https://doi.org/10.1002/hed.20267
Olsen, Randall J. ; Lydiatt, William M. ; Koepsell, Scott A ; Lydiatt, Daniel ; Johansson, Sonny L. ; Naumann, Sabine ; Bridge, Julia A. ; Neff, James R. ; Hinrichs, Steven Heye ; Tarantolo, Stefano R. / C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. In: Head and Neck. 2005 ; Vol. 27, No. 10. pp. 883-892.
@article{2d6863b0a1534e0fbc593e30871474be,
title = "C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck",
abstract = "Background. Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor. Methods. Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C-erb-B2 (HER2/ neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH). Results. The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen-targeted antibody therapy (trastuzumab) was initiated in two patients. Conclusions. These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities.",
keywords = "C-erb-B2, HER2/neu, Synovial sarcoma, Trastuzumab",
author = "Olsen, {Randall J.} and Lydiatt, {William M.} and Koepsell, {Scott A} and Daniel Lydiatt and Johansson, {Sonny L.} and Sabine Naumann and Bridge, {Julia A.} and Neff, {James R.} and Hinrichs, {Steven Heye} and Tarantolo, {Stefano R.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1002/hed.20267",
language = "English (US)",
volume = "27",
pages = "883--892",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

AU - Olsen, Randall J.

AU - Lydiatt, William M.

AU - Koepsell, Scott A

AU - Lydiatt, Daniel

AU - Johansson, Sonny L.

AU - Naumann, Sabine

AU - Bridge, Julia A.

AU - Neff, James R.

AU - Hinrichs, Steven Heye

AU - Tarantolo, Stefano R.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Background. Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor. Methods. Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C-erb-B2 (HER2/ neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH). Results. The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen-targeted antibody therapy (trastuzumab) was initiated in two patients. Conclusions. These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities.

AB - Background. Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor. Methods. Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C-erb-B2 (HER2/ neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH). Results. The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen-targeted antibody therapy (trastuzumab) was initiated in two patients. Conclusions. These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities.

KW - C-erb-B2

KW - HER2/neu

KW - Synovial sarcoma

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=25844472319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844472319&partnerID=8YFLogxK

U2 - 10.1002/hed.20267

DO - 10.1002/hed.20267

M3 - Article

C2 - 16158422

AN - SCOPUS:25844472319

VL - 27

SP - 883

EP - 892

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 10

ER -